Research Analysts Offer Predictions for Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Immunic in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter forecasts that the company will earn ($0.25) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic's Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $1.05 EPS.

Other analysts have also recently issued reports about the company. D. Boral Capital reaffirmed a "buy" rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday, April 30th. B. Riley reiterated a "buy" rating and issued a $6.00 target price on shares of Immunic in a report on Wednesday, April 16th. StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $13.20.

Immunic Stock Down 4.2 %

IMUX stock traded down $0.05 during midday trading on Friday, reaching $1.03. The company's stock had a trading volume of 388,186 shares, compared to its average volume of 700,853. The business's 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.10. Immunic has a 52 week low of $0.83 and a 52 week high of $2.11. The stock has a market cap of $98.21 million, a PE ratio of -0.83 and a beta of 1.73.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. bought a new position in Immunic in the fourth quarter valued at $37,000. Virtu Financial LLC bought a new position in shares of Immunic in the 3rd quarter valued at about $50,000. HB Wealth Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at about $81,000. Barclays PLC bought a new stake in Immunic during the fourth quarter worth about $84,000. Finally, Jane Street Group LLC boosted its position in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.